Volume 52, Issue 9, September 2022
Review Article
Management of elderly patients with unresectable pancreatic cancer
Some standard treatments for non-elderly patients with advanced pancreatic cancer could be applied for the elderly, but further studies are warranted to elucidate the indication criteria for each regimen using geriatric assessment.
Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan
Original Article
Dermatology
Appraisal of clinicopathological prognosticators in advanced acral lentiginous melanoma with characterization of PD-L1 and CD8/CD4 immunoprofiles
For Stage III/IV, non-BRAF acral lentiginous melanoma, microscopic evaluation of lymphovascular invasion, ulceration and tumor-infiltrating lymphocytes along with CD8/CD4 and PD-L1 immunoprofiles, may help predict patient survival.
Gastrointestinal Surgery
Salvage endoscopic resection for cT1N0M0 local recurrence after chemoradiotherapy for esophageal squamous cell carcinoma: endoscopic submucosal dissection versus endoscopic mucosal resection
Salvage endoscopic submucosal dissection is the effective treatment for local recurrence after chemoradiotherapy for esophageal cancer compared with salvage endoscopic resection.
Gynecology
Developing a novel DNA methylation risk score for survival and identification of prognostic gene mutations in endometrial cancer: a study based on TCGA data
A 5-CpG signature risk model was established with high AUC for the 5-year OS. Gene mutations were more likely in the low-risk group with favourable outcome.
Prevalence of sarcopenia in patients with gynecological cancer
We first reported the prevalence of sarcopenia stringently confirmed in accordance with the current international standard in patients with gynecological cancer.
Head & Neck
The prognostic value of S-100 protein and Ki-67 index in olfactory neuroblastoma
Our study evaluated the prognostic value of S-100 protein and Ki-67 labeling index in 85 patients with olfactory neuroblastomas, and our results suggested that they were reliable prognostic factors.
Hematology
Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy
A phase I study demonstrated tolerability and safety of HBI-8000 in Japanese patients with non-Hodgkin’s lymphoma. The maximum tolerated dose is 40 mg BIW. Preliminary efficacy results are encouraging.
Orthopedics/Sarcoma
A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610
Though JCOG1610 gave only descriptive results, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect in terms of relapse-free survival.
Efficacy and safety of tranexamic acid in patients undergoing surgery for bone and soft tissue tumors: a propensity score matching analysis
TXA administration safely and effectively reduces blood loss in patients undergoing surgery for BSTT with no increase in the rate of adverse events.
Palliative and Supportive Care
Association of a home-based nursing service during chemotherapy with the transfer to home care immediately after the last chemotherapy treatment in patients with advanced cancer
The effect of a home-based nursing service during chemotherapy on the place of care at the end of life is unknown. This retrospective study showed that it was significantly associated with the transfer to home care immediately after the last chemotherapy treatment.
Thoracic Surgery
Prognostic significance of visceral pleural invasion in patients with surgically resected small-cell lung cancer: a population-based study
Visceral pleural invasion is a useful and valid predictor in small-cell lung cancer, especially in patients with N0 disease. Clinicians should pay more attention to these patients.
Urology
Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study
Criteria adherence was not associated with unfavorable pathology with regard to radical prostatectomy in patients who opt for active surveillance.
Short communication
Pilot study of an artificial intelligence-based deep learning algorithm to predict time to castration-resistant prostate cancer for metastatic hormone-naïve prostate cancer
We developed an artificial intelligence-based deep learning algorithm for prediction of time to castration-resistant prostate cancer of >24 months or not in metastatic hormone-naïve prostate cancer.